Sutro Biopharma Inc reports results for the quarter ended in September - Earnings Summary

Sutro Biopharma

08/11/2022 23:25

* Sutro Biopharma Inc  STRO.OQ  reported a quarterly
adjusted loss
of 37 cents​​ per share for the quarter ended in September. The
mean expectation of eight analysts for the quarter was for a
loss of 74 cents per share.
    * Revenue rose 195.3% to $25.15 million from a year ago;
analysts
expected $12.68 million. 
    * Sutro Biopharma Inc's reported EPS for the quarter was a
loss
of 37 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Sutro Biopharma Inc shares had risen by 35.7% this
quarter and
lost 49.4% so far this year.
    * The company reported a quarterly loss of $19.49 million.
    * Wall Street's median 12-month price target for Sutro
Biopharma
Inc is $20.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 11:25 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.74          -0.37          Beat
 Jun. 30 2022      -0.46          -0.55          Missed
 Mar. 31 2022      -0.76          -0.84          Missed
 Dec. 31 2021      -0.69          -0.83          Missed